Clinical trials: R/R AML
Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
The purpose of this study is to determine the safety and tolerability of revumenib when given in combination with 2 different chemotherapy regimens in participants with relapsed/refractory acute leukemias harboring KMT2A…
- Conditions
- Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT05326516
- Testing
- Revumenib, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Where
- 11 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Syndax Pharmaceuticals
AML, NHL
A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS
This is a single-arm, open-label, dose-escalation and dose-expansion phase I clinical trial aimed at assessing the safety, tolerability, pharmacokinetic/pharmacodynamic profile, and preliminary efficacy of FD-001 capsules in the…
- Trial name
- NCT06731699
- Testing
- FD-001
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Chengdu FenDi Pharmaceutical Co., Ltd.
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
This phase II trial studies the side effects of enasidenib and sees how well it works in treating pediatric patients with acute myeloid leukemia that has come back after treatment (relapsed) or has been difficult to treat with…
- Trial name
- NCT04203316
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 28 sites in United States, Canada
- Volunteers
- 1 people
- Sponsor
- Children's Oncology Group
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with R/R AML irrespective the FLT3 status.
- Trial name
- NCT02626338
- Testing
- Crenolanib, Mitoxantrone, Cytarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Acute Myeloid Leukemia
Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML
This study is a single-center clinical study. The main purpose is an IIT clinical trial to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T injection in r/r AML subjects .
- Trial name
- NCT06110208
- Testing
- CLL1 and CD38 dual-target CAR-T injection
- Where
- China
- Volunteers
- 3 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
AML, MDS
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
This is a randomized, open-label, multicenter study to compare the efficacy and safety of AZA with or without ATRA in newly diagnosed unfit AML or Intermediate,High or Very High Risk MDS
- Conditions
- AML, MDS, Old Age; Debility, Hematologic Cancer
- Trial name
- NCT05175508
- Testing
- Azacitidine, all trans retinoic acid
- Where
- China
- Volunteers
- 180 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Relapsed/Refractory AML
Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients
This study will evaluate the safety and tolerability of uproleselan(GMI-1271), a specific E-selectin antagonist, and characterize the pharmacokinetic (PK) profile of uproleselan, in combination with chemotherapy to treat Chinese…
- Trial name
- NCT04839341
- Testing
- Uproleselan
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- Apollomics Inc.
AML
NKG2D CAR-NK & r/rAML
This trial will explore the maximum tolerated dose（MTD）of NKG2D CAR-NK cells in the treatment of relapsed or/and refractory AML in a dose-escalation manner, and observe the clinical safety and efficacy.
- Trial name
- NCT05734898
- Testing
- NKG2D CAR-NK
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Hematopoietic System--Cancer
Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML
No more datas about post-transplant cyclophosphamide (PT/Cy) used in pediatric refractory acute myeloid leukemia (R-AML）patients.
- Trial name
- NCT03654703
- Testing
- Cyclophosphamide
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Capital Research Institute of Pediatrics